Two-Dimensional Speckle Tracking Echocardiography Demonstrates No Effect of Active Acromegaly on Left Ventricular Strain
Presentation Number: SUN 442
Date of Presentation: April 2nd, 2017
Leandro Kasuki*1, Isabela Volschan2, Cintia M. dos Santos Silva3, Mônica L. Alcantara4, Roberto M. Saraiva5, Sérgio Salles Xavier6 and Mônica R Gadelha7
1Hospital Universitário Clementino Fraga Filho - UFRJ, Rio de Janeiro, Brazil, 2Hospital Universitário Clementino Fraga Filho - UFRJ, Rio de janeiro, Brazil, 3Hospital Universitário Clementino Fraga Filho- UFRJ, Rio De Janeiro, Brazil, 4Hospital Samaritano, Rio de Janeiro, Brazil, 5Instituto Nacional de Infectologia Evandro Chagas- FIOCRUZ, Rio de Janeiro, Brazil, 6Hospital Universitário Clementino Fraga Filho- UFRJ, Rio de Janeiro, Brazil, 7Medical School and Hospital Universitário Clementino, Rio De Janeiro-RJ
Background: Acromegaly is a rare disease that is characterized by increased serum growth hormone (GH) and insulin-like growth fator type I (IGF-I) levels, usually due to GH-secreting pituitary adenoma. Cardiac disease may be present in acromegaly and some studies suggest that cardiovascular disease may contribue to the increased mortality. Two-dimensional (2D) speckle tracking echocardiography (STE) allows for the study of myocardial strain (ε), a marker of early and subclinical ventricular systolic dysfunction; however, STE has never been used to evaluate acromegaly patients.
Aim: To evaluate left ventricular (LV) global longitudinal strain (GLS) in patients with active acromegaly in comparison with a control group.
Methods: Cross-sectional clinical study. Consecutive patients with active acromegaly with no detectable heart disease and a control group that were matched for age, gender, arterial hypertension and diabetes mellitus underwent STE. GLS, left ventricular mass index (LVMi), left ventricular ejection fraction (LVEF) and relative wall thickness (RWT) were obtained via 2D echocardiography using STE.
Results: Thirty-seven patients with active acromegaly (mean age 45.6 ± 13.8; 48.6% were males) and 48 controls were included. The mean GLS was not significantly different between the acromegaly group and the control group (in %, -20.1 ± 3.1 vs. -19.4 ± 2.2, p=0.256). Mean LVMi was increased in the acromegaly group (in g/m2, 101.6 ± 27.1 vs. 73.2 ± 18.6, p< 0.01). There was a negative correlation between LVMi and GLS (r= -0.39, p= 0.01).
Conclusions: Acromegaly patients despite presenting with a higher LVMi when analysed by 2D echocardiography did not present with impairment in the strain when compared to a control group, this finding indicates a low chance of evolution to systolic dysfunction.
Disclosure: LK: , Novartis, Pfizer. MRG: Advisory Group Member, Ipsen, Pfizer. Nothing to Disclose: IV, CMDSS, MLA, RMS, SSX